Novo Nordisk CEO pledges five blockbuster drugs by 2030 as patent cliff looms

Novo Nordisk's CEO announced plans to launch over five billion-dollar drugs by 2030 and generate $23 billion in sales from pipeline products by 2035, aiming to offset the patent expiration of semaglutide (Ozempic/Wegovy) in the early 2030s. Shares fell up to 9% on analyst skepticism about pricing power and pipeline execution. The announcement is a strategic response to a known overhang, but market reaction suggests low confidence in the targets.